of umeclidinium to dual therapy, when treating patients with poorly controlled asthma,
showed a greater improvement in lung function compared with dual therapy alone.
The side effects reported in this study were limited.
Are there plans for further studies?
Other studies of fluticasone furoate, umeclidinium, and vilanterol in patients with
asthma have been conducted and more are being planned.
Where can I find more information about this study?
Clinical studies have unique study numbers that are included in publications and other
information about the study. The unique study numbers associated with this study are
shown below with internet links to scientific summaries and other information.
The scientific summaries include more details about the requirements for study
enrolment, the study visit schedule, results from other endpoints and more detailed
information about adverse events.
Organisation Website Study Number
European Medicines
www.clinicaltrialsregister.eu 2016-001304-371
Agency
United States National
www.clinicaltrials.gov NCT029246882
Institutes of Health (NIH)
Your doctor can help you understand more about this study and the results. Speak to
your doctor about the treatment options available in your country. You should not
make changes to your care based on the results of this or any single study. Keep taking
your current treatment unless instructed by your doctor.
We would like to thank the patients who contributed to this study. The results of this
study will help answer scientific questions about treating patients with asthma.
The content for this document was finalised by GSK on the 27th of January 2020. The
information in this summary does not include additional information available after this
date.
1https://www.clinicaltrialsregister.eu/ctr-search/search?query=2016-001304-37
2https://clinicaltrials.gov/ct2/show/study/NCT02924688